NZ772266A - Pegylated tetanus neurotoxins and treatment of hypotonia - Google Patents

Pegylated tetanus neurotoxins and treatment of hypotonia

Info

Publication number
NZ772266A
NZ772266A NZ772266A NZ77226619A NZ772266A NZ 772266 A NZ772266 A NZ 772266A NZ 772266 A NZ772266 A NZ 772266A NZ 77226619 A NZ77226619 A NZ 77226619A NZ 772266 A NZ772266 A NZ 772266A
Authority
NZ
New Zealand
Prior art keywords
hypotonia
treatment
peg
tents
tent
Prior art date
Application number
NZ772266A
Inventor
Thomas Mclean
Peter Smooker
Luke Norbury
Peter Coloe
Russell Conduit
Anthony Sasse
Original Assignee
Snoretox Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2018902779A external-priority patent/AU2018902779A0/en
Application filed by Snoretox Pty Ltd filed Critical Snoretox Pty Ltd
Publication of NZ772266A publication Critical patent/NZ772266A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24068—Tentoxilysin (3.4.24.68), i.e. tetanus neurotoxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Detergent Compositions (AREA)

Abstract

The invention relates to a composition comprising a first PEGylated tetanus neurotoxin (PEG-TeNT) comprising tetanus neurotoxin (TeNT) conjugated to polyethylene glycol (PEG) and a second TeNT. The invention also relates to various PEG-TeNTs. The invention also relates to a method of treating hypotonia using the composition or various PEG-TeNTs, and a kit comprising the composition or various PEG-TeNTs. In one embodiment, the hypotonia is obstructive sleep apnoea.
NZ772266A 2018-07-31 2019-07-30 Pegylated tetanus neurotoxins and treatment of hypotonia NZ772266A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2018902779A AU2018902779A0 (en) 2018-07-31 Composition and method
PCT/AU2019/050793 WO2020024002A1 (en) 2018-07-31 2019-07-30 Pegylated tetanus neurotoxins and treatment of hypotonia

Publications (1)

Publication Number Publication Date
NZ772266A true NZ772266A (en) 2022-09-30

Family

ID=69230503

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ772266A NZ772266A (en) 2018-07-31 2019-07-30 Pegylated tetanus neurotoxins and treatment of hypotonia

Country Status (12)

Country Link
US (1) US20210353724A1 (en)
EP (2) EP3830110A4 (en)
JP (2) JP2021533201A (en)
KR (1) KR20210040407A (en)
CN (1) CN112638937A (en)
AU (1) AU2019315327B2 (en)
BR (1) BR112021001520A2 (en)
CA (2) CA3108079C (en)
MX (1) MX2021001181A (en)
NZ (1) NZ772266A (en)
SG (1) SG11202100646SA (en)
WO (1) WO2020024002A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4417131A1 (en) 2023-02-15 2024-08-21 Canon Medical Systems Corporation X-ray diagnostic apparatus, x-ray diagnostic system, and x-ray diagnostic method

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003200441B2 (en) * 1998-04-29 2006-07-06 Allergan, Inc. Compositions and methods for modulating neural sprouting
GB9914861D0 (en) * 1999-06-25 1999-08-25 Imperial College Tetanus toxin polypeptides
IL153734A0 (en) * 2000-06-28 2003-07-06 Ira Sanders Methods for using tetanus toxin for beneficial purposes in animals (mammals)
US20020197278A1 (en) 2001-06-21 2002-12-26 Surromed, Inc. Covalent coupling of botulinum toxin with polyethylene glycol
NZ537120A (en) * 2002-05-31 2008-07-31 Univ Jefferson Compositions and methods for transepithelial molecular transport
WO2008024879A1 (en) * 2006-08-25 2008-02-28 University Of Maryland, Baltimore Use of tetanus toxin to amplify inadequate voluntary muscle contraction or to improve muscle tone in an animal actively vaccinated against the toxin and a regimen for treatment
CN102414564B (en) * 2009-04-27 2015-01-21 莫茨制药有限及两合公司 Means and methods for the determination of the amount of neurotoxin polypeptide and of its catalytic and proteolytic activities
DK2547364T3 (en) * 2010-03-15 2017-02-27 Academisch Ziekenhuis Leiden Peptides, conjugates and methods for increasing the immunogenicity of a vaccine
KR20170044093A (en) 2014-07-02 2017-04-24 스페리움 바이오메드 에스.엘. Methods of increasing muscle mass using non-toxic tetanus toxin c fragment (ttc)
JP2018525021A (en) * 2015-08-27 2018-09-06 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ Compositions and methods for the treatment of pain
CN106692963B (en) * 2016-12-28 2020-12-22 中国人民解放军军事医学科学院生物工程研究所 Combined vaccine for preventing staphylococcus aureus infection and tetanus
EP3723784A4 (en) * 2017-12-15 2022-01-12 The Medical College of Wisconsin, Inc. Modified clostridial neurotoxins as vaccines and conjugate vaccine platforms

Also Published As

Publication number Publication date
EP4134133A1 (en) 2023-02-15
AU2019315327B2 (en) 2024-05-09
MX2021001181A (en) 2021-04-19
CN112638937A (en) 2021-04-09
JP2024014975A (en) 2024-02-01
KR20210040407A (en) 2021-04-13
EP3830110A1 (en) 2021-06-09
CA3108079C (en) 2023-10-10
SG11202100646SA (en) 2021-02-25
BR112021001520A2 (en) 2021-04-20
JP2021533201A (en) 2021-12-02
CA3167665A1 (en) 2020-02-06
AU2019315327A1 (en) 2021-02-11
WO2020024002A1 (en) 2020-02-06
US20210353724A1 (en) 2021-11-18
CA3108079A1 (en) 2020-02-06
EP3830110A4 (en) 2022-03-02

Similar Documents

Publication Publication Date Title
PH12019501575A1 (en) ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF
WO2013153550A3 (en) Reverse thermal hydrogel preparations for use in the treatment of disorders of the urothelium
NZ749962A (en) Pegylated porcine interferon and methods of use thereof
ATE499088T1 (en) GLP-1-FC FUSION PROTEIN FORMULATION
PH12020500197A1 (en) Use of inhaled nitric oxide for the treatment of pulmonary hypertension associated with lung disease
DE60142839D1 (en) Botulinum toxin for the treatment of acute skeletal muscle damage
CY1110980T1 (en) Peptide Combination Vaccine Against Cats Allergy
EA202091286A1 (en) APPLICATION OF INHALED NITROGEN (II) OXIDE AND OXIDE FOR THE TREATMENT OF PULMONARY HYPERTENSION
MX2019009860A (en) Improved use of botulinum neurotoxin in the treatment of sialorrhea.
MX2022010186A (en) Botulinum neurotoxins for use in therapy.
WO2010039538A3 (en) Flavivirus inhibitors and methods for their use
CR11692A (en) USE OF PEGylated IGF-I VARIATIONS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS
SE0300971D0 (en) Nitric oxide in the treatment of inflammation
MX2007008764A (en) Methods for treating adhesive capsulitis.
MX2022001896A (en) High concentration anti-c5 formulations.
NZ772266A (en) Pegylated tetanus neurotoxins and treatment of hypotonia
WO2006135493A3 (en) A composition for wound healing and use thereof
BR112022012473A2 (en) HAIR TREATMENT COMPOSITION, AND METHODS TO TREAT HAIR, TO IMPROVE HAIR CONDITION AND TO LOWER HAIR PH
LU92202I2 (en) aflibercept
MX2018005352A (en) Methods and compositions for the treatment of amyloidosis.
MX2021004755A (en) Use of plasma and plasma fractions for improvement of pain, wound healing, and postoperative recovery.
MX2022015071A (en) Anti-bk virus antibody molecules.
MX2024002779A (en) Multivalent pneumococcal vaccines.
FR2896693B1 (en) COMPOSITION COMPRISING SEVERAL BOTULINOUS TOXINS
ES2421407T3 (en) Wound healing agent and composition

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 JUL 2024 BY GRIFFITH HACK

Effective date: 20230630

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 JUL 2025 BY GRIFFITH HACK

Effective date: 20240627